Clinical Trial Update: Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating fulvestrant with MK-0646 (dalotuzumab) and dasatinib for metastatic hormone receptor-positive, HER2-negative breast cancer was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• MK-0646 (dalotuzumab)
• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-02-02